Abstract |
Tacrolimus hydrate ( FK506) reduces myasthenic symptoms due to its immunosuppressive properties. We studied the therapeutic effects of FK506 and noted improvement in 7 of 13 myasthenic patients on the clinical muscle test ( myasthenia gravis, MG score). Two other patients with relapsing ocular symptoms improved. We also examined patient sensitivity to FK506, but could not predict such sensitivity before FK506 treatment in the present study.
|
Authors | Nobuo Wakata, Toyokazu Saito, Sachiko Tanaka, Toshihiko Hirano, Kitaro Oka |
Journal | Clinical neurology and neurosurgery
(Clin Neurol Neurosurg)
Vol. 106
Issue 1
Pg. 5-8
(Dec 2003)
ISSN: 0303-8467 [Print] Netherlands |
PMID | 14643908
(Publication Type: Journal Article)
|
Chemical References |
- Immunosuppressive Agents
- Prednisolone
- Tacrolimus
|
Topics |
- Adult
- Aged
- Combined Modality Therapy
- Female
- Humans
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Myasthenia Gravis
(diagnosis, drug therapy, immunology)
- Neurologic Examination
(drug effects)
- Patient Selection
- Prednisolone
(therapeutic use)
- Tacrolimus
(adverse effects, therapeutic use)
- Thymectomy
- Treatment Outcome
|